<DOC>
	<DOCNO>NCT01953692</DOCNO>
	<brief_summary>The purpose trial evaluate safety , tolerability , efficacy pembrolizumab ( MK-3475 , KEYTRUDAÂ® ) hematologic malignancy . The primary study hypothesis treatment pembrolizumab result clinically meaningful improvement Objective Response Rate ( ORR ) Complete Remission Rate ( CRR ) .</brief_summary>
	<brief_title>A Trial Pembrolizumab ( MK-3475 ) Participants With Blood Cancers ( MK-3475-013 ) ( KEYNOTE-013 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion criterion : Has confirm diagnosis relapse refractory Multiple Myeloma , Primary mediastinal Large B cell Lymphoma , nonHodgkin lymphoma ( NHL ) , Follicular Lymphoma , Diffuse Large B cell lymphoma , Hodgkin lymphoma Myelodysplastic syndrome . Has measureable disease Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Demonstrates adequate organ function Prior therapy criterion must meet Is currently participate receive study therapy participate study investigational agent use investigational device within 4 week first dose study therapy Has undergone prior allogeneic hematopoietic stem cell transplantation within last 5 year , receive live vaccine within 30 day plan start study therapy , receive prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 , receive monoclonal antibody within 4 week prior study Day 1 recover adverse event due previously administer agent Has know clinically active central nervous system ( CNS ) involvement Has history ( noninfectious ) pneumonitis require steroid current pneumonitis Has evidence interstitial lung disease , active noninfectious pneumonitis , know additional malignancy progress require active treatment , active infection require intravenous systemic therapy , active autoimmune disease require systemic therapy , know Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( HBV ) , Hepatitis C ( HCV ) infection Is pregnant breastfeeding , expect conceive father child within project duration trial Has receive prior therapy antiprogrammed cell death 1 ( antiPD1 ) , antiprogrammed cell death ligand 1 ( antiPDL1 ) , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) Has know symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>